Alkermes Plc (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,000 shares of the firm’s stock in a transaction dated Friday, November 2nd. The shares were sold at an average price of $37.51, for a total value of $37,510.00. Following the transaction, the director now owns 8,000 shares of the company’s stock, valued at approximately $300,080. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NASDAQ:ALKS opened at $37.74 on Monday. Alkermes Plc has a 1 year low of $37.01 and a 1 year high of $71.22. The company has a market cap of $5.86 billion, a price-to-earnings ratio of -102.00 and a beta of 1.61. The company has a quick ratio of 2.56, a current ratio of 2.85 and a debt-to-equity ratio of 0.24.
Alkermes (NASDAQ:ALKS) last announced its earnings results on Tuesday, October 23rd. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.15. Alkermes had a negative return on equity of 0.12% and a negative net margin of 13.23%. The business had revenue of $248.72 million during the quarter, compared to analyst estimates of $236.70 million. During the same quarter in the previous year, the business earned $0.03 earnings per share. The company’s revenue for the quarter was up 14.4% compared to the same quarter last year. Analysts anticipate that Alkermes Plc will post -0.5 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in ALKS. First Trust Advisors LP boosted its position in shares of Alkermes by 67.1% during the third quarter. First Trust Advisors LP now owns 2,196,134 shares of the company’s stock valued at $93,204,000 after buying an additional 881,946 shares during the period. First Manhattan Co. raised its stake in shares of Alkermes by 55,499.4% during the third quarter. First Manhattan Co. now owns 555,994 shares of the company’s stock valued at $23,596,000 after acquiring an additional 554,994 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in shares of Alkermes by 116.1% during the second quarter. Canada Pension Plan Investment Board now owns 418,861 shares of the company’s stock valued at $17,240,000 after acquiring an additional 224,998 shares in the last quarter. Rhenman & Partners Asset Management AB raised its stake in shares of Alkermes by 219.4% during the second quarter. Rhenman & Partners Asset Management AB now owns 290,000 shares of the company’s stock valued at $11,936,000 after acquiring an additional 199,200 shares in the last quarter. Finally, C WorldWide Group Holding A S bought a new stake in shares of Alkermes during the second quarter valued at approximately $6,646,000.
Several research analysts recently commented on ALKS shares. ValuEngine upgraded Alkermes from a “sell” rating to a “hold” rating in a research report on Friday, October 26th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Alkermes in a research report on Sunday, July 8th. Stifel Nicolaus dropped their price target on Alkermes from $44.00 to $40.00 and set a “hold” rating for the company in a research report on Friday. Cantor Fitzgerald restated a “hold” rating and set a $46.00 target price on shares of Alkermes in a research report on Tuesday, October 23rd. Finally, Bank of America dropped their target price on Alkermes from $56.00 to $54.00 and set a “buy” rating for the company in a research report on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $53.64.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes.
Featured Story: Price to Earnings Ratio (PE)
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.